Foundation for Sarcoidosis Research Launches Say Sarcoidosis Campaign to Shed Light on the 1.2 Million People Impacted by Sarcoidosis for April’s Awareness Month
01 avr. 2024 07h41 HE
|
Foundation for Sarcoidosis Research
FSR Launches Say Sarcoidosis campaign for April's Awareness Month
26 Patient Volunteer Leaders Attend the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic
27 mars 2024 06h41 HE
|
Foundation for Sarcoidosis Research
26 Patient Volunteer Leaders joined the Foundation for Sarcoidosis Research at Cleveland Clinic for the Leadership Advanced Training Conference
Tiny Health, Pioneer of the First At-Home Baby Gut Microbiome Test, Aims to Address the Pediatric Chronic Conditions Crisis
05 mars 2024 09h00 HE
|
Tiny Health
AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Tiny Health, the first at-home gut microbiome test developed for babies, today announced a $8.5 million Series A round led by Spero Ventures,...
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
04 mars 2024 01h15 HE
|
Novartis Pharma AG
The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies...
Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
15 févr. 2024 06h23 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.
The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis
18 déc. 2023 15h41 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis.
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
09 nov. 2023 11h00 HE
|
Novartis Pharma AG
In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria...
Foundation for Sarcoidosis Research Announces 3 New Members to the 40 Member FSR Global Sarcoidosis Clinic Alliance through its FSR-GSCA Capacity Building Grants
01 nov. 2023 11h26 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research announces three clinics that have been selected as members of FSR Global Sarcoidosis Clinic Alliance
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
31 oct. 2023 16h50 HE
|
Novartis Pharma AG
FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A inhibitor...
Foundation for Sarcoidosis Research announces largest Global Sarcoidosis Virtual Summit – Find Your Community, Find Your Life
26 sept. 2023 09h15 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research to Host Largest Virtual Sarcoidosis Educational Event of the Year